Alira Health

Alira Health

The Promise and Reality of NGTs

Watch and Listen to 2022’s Summer Special episode

Our Transformation Talks Summer Special is here!

Next Generation Therapies (NGTs) currently in development will deliver treatments that address the underlying cause of diseases, disrupt the biopharmaceutical environment, and offer a life-long solution to patients. They create unprecedented opportunities for patients and will be measurable in lives saved, disabilities reduced, and overall quality of life improvements. However, along with these benefits come unprecedented challenges for insurance coverage, reimbursement, and payment.

Tune in to learn about risks and challenges in developing NGTs, bringing them to the market, and how NGTs can change patients’ lives once their value is understood and correctly attributed by the decision makers / payers.

This special episode is not only be available in audio format but also in video and features a stellar group of guests:

  • Andrea Mantovani – Vice President, Global Market Access and Pricing, Alira Health
  • Oswald Bentinck – Vice President – Head of Market Access EMEA, Novartis Gene Therapies
  • Pietro Sternini – Executive Director, Gene Therapy Market Access & Marketing Lead, EMEA, Astellas Gene Therapies
Watch the episode “The Promise and Reality of NGTs”:

Listen to the episode:

The episode “The Promise and Reality of Next Generation Therapies” is also available on the following platforms:

Google Podcasts      Spotify

Webinars
Published on:
July 20, 2022
Meet our speakers:
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access and Pricing, Alira Health
Oswald Bentinck headshot

Oswald Bentinck

Vice President - Head of Market Access EMEA, Novartis Gene Therapies
Pietro Sternini headshot

Pietro Sternini

Executive Director, Gene Therapy Market Access & Marketing Lead, EMEA, Astellas Gene Therapies
Meet our host:
Kenny Carberry

Kenny Carberry

Director, Clinical Development, Alira Health

Related news

Articles July 4, 2024
Navigating Market Access for Rare Diseases: The Potential of Real-World Evidence
Our experts answer common questions about the strategic need for real-world evidence to drive market access for rare diseases.
Market Access Rare Disease Real-World Evidence (RWE)
Case Studies June 27, 2024
A Multinational Pharma Targeting Myasthenia Gravis Garners Payer Advice on Market Access
Our client sought to incorporate early payer advice on the MG clinical trial design, identify evidence gaps, and provide insights on the overall development program for the asset.
Market Access Myasthenia Gravis (MG) Rare Disease
Articles March 18, 2024
WHO Model Lists of Essential Medicines: What You Need to Know 
Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in interactions with the WHO.
Market Access
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
News January 24, 2024
Alira Health and AseBio Announce Market Access Mentoring Program for 2024
Alira Health and AseBio, the Spanish Bioindustry Association, are pleased to announce the 2024 edition of their market access mentoring program for AseBio members.
Biotech Market Access Spain Startups
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
News January 18, 2024
Alira Health and Biocat Announce Startup Support Program for 2024
Alira Health and Biocat, a strategic stakeholder building the Catalan life sciences and ecosystem, partnered to foster Market Access for startups.
Market Access Startups
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.